EE261 Cost-Effectiveness of Adding Darolutamide to Docetaxel and Androgen Deprivation Therapy in the Treatment of Metastatic Hormone-Sensitive Prostrate Cancer

Abstract

Authors

I.B. Nwogu J. Nedzesky J.J. Carlson

Full Text Cite This Article
Back to Volume 26, Supplemental Issue 6S
Your browser is out-of-date

ISPOR recommends that you update your browser for more security, speed and the best experience on ispor.org. Update my browser now

×